Conference abstractPublished 11 Feb 2020
Oxsealife: Embarking on a new methodology to treat haemorrhagic shock that focuses on cell recovery
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Haemorrhagic shock is the result of inadequate blood flow to meet the metabolic demands of organs resulting in a flow dependent impairment of oxygen consumption by cells. Severe hemorrhage and ischaemia triggers a cascade of intracellular events that induce mitochondrial dysfunction and multiorgan failure. Therefore, patient survival after severe haemorrhagic shock depends on restoration of microvascular perfusion, tissue oxygen delivery, endothelial function and cell integrity. We investigated a novel crystalloid fluid designed for tissue oxygen delivery, Oxsealife®, with components to generate microvascular nitric oxide and scavenge reactive oxygen species generated during ischaemia- reperfusion injury. The amount of dissolved oxygen in blood progressively increased during step- wise in- vitro haemodilution with this fluid, demonstrating that the oxygen solubility coefficient of blood is dynamic, not static. We performed a pilot study to compare resuscitation with this novel crystalloid vs whole blood transfusion in a swine haemorrhagic shock model with animals bled to an arterial lactate oxygen debt target. Despite contributing no haemoglobin, viscosity nor oncotic potential, resuscitation with Oxsealife® after severe haemorrhagic shock restored central haemodynamic parameters comparable to stored allogeneic blood transfusion. Tissue perfusion, oxygenation and metabolic outcomes were equivalent between treatment groups. Increased consumption of bicarbonate in animals given Oxsealife® suggested greater capillary recruitment and enhanced clearance of lactate accumulated in tissues. Serum markers of organ function, animal activity during recovery, and histological analysis of tissue morphology and endothelial glycocalyx integrity confirmed functional recovery from haemorrhagic shock. We conclude that recovery of tissue oxygen delivery and organ function after haemorrhagic shock is not dependent on treatments that increase haemoglobin levels. Oxsealife® shows promise for treatment of severe haemorrhagic shock, and may reduce requirement for allogeneic blood products.
Keywords
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Immune Disorders & Therapy
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Lara Oller”
